DailyStocks Stock Article Search

979 Spam-Free Article(s) Found

Sort:

Date

Filter:

All

DeepLinks

Symbol	Name	Last Close	Mkt Cap	DailyStocks' Rating Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.	Vote Now! Monday’s Close
BIIB	Biogen Inc.	$334.44	$67.37B	Downtrend	Up Down

Article Searches

http://www.briefing.com/investor/popuppages/articlepopup.aspx?articleId=UD20190222122913 Feb 22, 2019 - BMO Capital Markets issues rating change for BIIB 0

https://seekingalpha.com/article/4240000-abbvie-suffers-market-loss-humira-europe-u-s-different-story?source=feed_sector_healthcare Feb 11, 2019 - AbbVie missed its Q4 earnings expectations, but it does have many other products to help it get back on track in the coming quarters.The big loss for the quarter was due to international sales of Humi 0

http://www.zacks.com/research-daily/211963/top-research-reports-for-visa-charter-communications-biogen?cid=CS-ZC-FT-211963 Feb 08, 2019 - Top Research Reports for Visa, Charter Communications & Biogen 0

https://seekingalpha.com/article/4237809-clearbridge-cap-growth-strategy-portfolio-manager-commentary-q4-2018?source=feed_all_articles Feb 04, 2019 - 0

http://feeds.benzinga.com/~r/benzinga/~3/F25es8s5L7w/ionis-wins-price-target-hike-on-partner-biogens-guidanc Jan 30, 2019 -

Ionis Pharmaceuticals Inc (NASDAQ: IONS)'s partner Biogen Inc (NASDAQ: BIIB) reported

https://seekingalpha.com/article/4236353-biogen-inc-biib-ceo-michel-vounatsos-q4-2018-results-earnings-call-transcript?source=feed_sector_healthcare Jan 29, 2019 - 0

https://www.fool.com/earnings/call-transcripts/2019/01/29/biogen-inc-biib-q4-2018-earnings-conference-call-t.aspx?source=iedfolrf0000001 Jan 29, 2019 - BIIB earnings call for the period ending December 31, 2018. 0

http://www.zacks.com/stock/news/350499/biogen-biib-q4-earnings-beat-estimates-revenues-up-y-y?cid=CS-ZC-FT-350499 Jan 29, 2019 - Biogen (BIIB) beats estimates for both earnings and sales in the fourth quarter of 2018, driven by higher sales of Spinraza. 0

https://seekingalpha.com/article/4236192-biogen-inc-2018-q4-results-earnings-call-slides?source=feed_sector_healthcare Jan 29, 2019 - The following slide deck was published by Biogen Inc. in conjunction with their 2018 Q4 earnings call. 0

https://seekingalpha.com/article/4236113-biotech-bio-series-5-stay-clear-biogen?source=feed_sector_healthcare Jan 28, 2019 - Biogen’s largest revenue driver, its multiple sclerosis franchise, has seen stagnant growth and has a bleak future ahead.Its new drug Spinraza is growing strong but faces severe impending competition 0

Pages: 12 3 4 5 6...98

Page 1>

Related Companies

	Name	Exchange	Price	Mkt Cap
GILD	Gilead Sciences, Inc.	NASDAQ	$72.78	$94.35B
SGEN	Seattle Genetics, Inc.	NASDAQ	$76.15	$12.09B
NBIX	Neurocrine Biosciences, Inc.	NASDAQ	$117.38	$10.62B
QGEN	Qiagen N.V.	NASDAQ	$37.42	$8.5B
QGEN	Qiagen N.V.	NYSE	$37.42	$8.5B

Sector: Health Care > Industry: Biotechnology: Biological Products (No Diagnostic Substances)

http://www.nasdaq.com/symbol/biib Quote information directly from the exchange SEC filings Comparison Ownership Insiders Institutions Revenue/EPS Competitors Guru Report Analysts Pre-market Quote Consultant After hours Transcripts

https://www.google.com/finance?q=BIIB Industry related info and international coverage Summary News

http://www.bloomberg.com/research/stocks/snapshot/snapshot.asp?ticker=BIIB Original news and commentary from Bloomberg Charts Financials with pensions Snapshot Earnings Transactions People Options